• Nuvation Bio priced USD 287.5 million of 0.75% Convertible Senior Notes due 2032 following full exercise of the USD 37.5 million greenshoe.
• Net proceeds estimated at about USD 277.6 million, reflecting underwriting discounts and offering expenses.
• USD 2.2 million of the greenshoe proceeds allocated to additional capped call transactions with a USD 10.46 cap price.
• Remaining greenshoe proceeds earmarked for general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607061709PR_NEWS_USPR_____NY98960) on July 06, 2026, and is solely responsible for the information contained therein.